Expeditors International of Washington heads into its November earnings with a stock trading above most analyst targets, a new bearish initiation landing this week, and short interest that remains quietly subdued.
The most pressing tension for EXPD right now is the gap between where the stock trades and where the Street thinks it should. At $188.16, EXPD sits roughly 5.5% above the consensus mean price target of $178.20. BNP Paribas added to the sceptical camp this week, initiating coverage with a Neutral rating and a $180 target, essentially in line with consensus but 4% below the current price. Barclays, also out this week, raised its Underweight target from $160 to $165, a concession to the stock's strength but still a call for 12% downside. Against those cautious voices, UBS holds a Buy with a $210 target after lifting it following August earnings, and B of A Securities remains at Buy with a $189 target from July. JP Morgan upgraded to Neutral in August from Underweight, neutralising what had been another bearish voice. The net picture is a hold consensus with 10 hold ratings on the book, bulls concentrated at the upper end of the range and the bears digging in just below where the stock is trading today.
The positioning data supports the idea that this is not a heavily contested name. Short interest is 3.2% of free float, down about 10.5% over the past month even as it has crept up fractionally over the past week to 4.29 million shares. Borrow conditions are extremely loose: availability is running at over 7,300%, meaning shares to borrow dwarf the current short position by a factor of roughly 73. Cost to borrow is 0.45%, down 15% on the week, firmly in low territory. The ORTEX short score of 36.6 places EXPD in the lower half of the universe, consistent with the read that bears are not building conviction here. Options tell the same relaxed story. The put/call ratio is 0.28, almost exactly in line with its 20-day average, with a z-score near zero. The 52-week high for the PCR was 0.73 back in August, a reading the market has long since walked away from.
Valuation multiples add texture to the Street's caution. EXPD trades at 23.8 times earnings and 9.3 times book, with both ratios drifting lower over the past month as the stock has pulled back roughly 1.5% from its August peak. EV/EBITDA is 17.1, also edging down. The factor score picture is mixed: EPS surprise ranks in the 79th percentile, a sign the company has consistently beaten estimates, and the 90-day EPS momentum score is 81. But 12-month forward EPS growth scores only in the 33rd percentile, suggesting the Street is not modelling acceleration from here. The EV/EBIT factor scores just 32, pointing to a name priced for quality rather than value.
The company's own alt data adds one piece of colour. Wikipedia page views are running at a z-score of 1.59 against EXPD's own 90-day history, the highest retail attention reading in the recent window. This tracks with the stock's year-to-date gain of roughly 27%, which has drawn more eyes to the name. That dataset carries no measured lead to EXPD's financials, so it is background context rather than a signal for the November print.
Among the closest peers, CHRW was broadly flat on the week, while UPS fell 2% and HUBG dropped 5.6%. EXPD's relative resilience confirms the pattern from recent weeks: the asset-light forwarding model is holding up better than asset-heavy names when freight sentiment softens. The November 3 earnings date is now 34 days out, and with the two most recent prints delivering next-day gains of 6% and 8% respectively, the earnings history argues the stock can reward on the day. What to watch in the interim is whether the string of analyst target cuts and neutral initiations near current levels widens into a more material downgrade cycle, or whether the bull camp at UBS and B of A finds company.
See the live data behind this article on ORTEX.
Open EXPD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
